Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28245)	2/18/1999 12:00:00 PM
From: Machaon	Respond to of 32384

"the return of Targretin rights will now permit us to rapidly generate revenues" Henry, I find Robinson's choice of words interesting. The phase II trials for Breast Cancer and Psoriasis are due for completion this year. From his statement, it implies that the trials are going well. How else could his statement be interpreted? He expects rapid generation of revenues from Targretin. Could this be a misleading statement from Robinson, or could he be predicting an FDA approval for Targretin in CTCL, and off label Targretin uses for either Breast Cancer or Psoriasis by 2000? << if Targretin oral cost $20 per pill for cancer and $2 per pill for diabetes, it would be harder to sell the $20 pills >> This is strange. If I was a cancer doctor, I would diagnose my patient as having diabetes and prescribe Targretin at $2 a pill rather than $20.